Evidence map›Paper›PMID 41097756›Full record

ArticleCancers2025

Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional Review.

Joy Justice, Hannah Burnette, Rebecca Irlmeier, Fei Ye, Douglas B Johnson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joy JusticeSchool of Medicine, Vanderbilt University, 1161 21st Ave. S, Nashville, TN 37232, USA.ORCID 0009-0001-8984-1249
Hannah BurnetteDepartment of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave., Nashville, TN 37232, USA.ORCID 0009-0009-7784-634X
Rebecca IrlmeierDepartment of Biostatistics, Vanderbilt University Medical Center, 1211 Medical Center Dr., Nashville, TN 37203, USA.
Fei YeDepartment of Biostatistics, Vanderbilt University Medical Center, 1211 Medical Center Dr., Nashville, TN 37203, USA.ORCID 0000-0001-6472-5076
Douglas B JohnsonDepartment of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave., Nashville, TN 37232, USA.

Funding

MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities Grant Grant U54CA163072
6 · The paper itself

Abstract

BACKGROUND/

objectivesImmune checkpoint inhibitors (ICIs) have revolutionized outcomes for patients with melanoma. As such, it is important to understand factors that may influence response as well as toxicity to these therapies. Impaired glucose control is often a sign of pathologic inflammation and may alter immune system regulation, but it is unclear whether glucose control impacts patients with melanoma on ICIs.

methodsAfter reviewing patients with melanoma treated with ICIs at our institution between 2014 and 2024, we assessed whether longitudinal glucose control is associated with patient outcomes (response, progression-free survival, overall survival, and treatment toxicity) during ICI therapy.

resultsThere was no significant difference in baseline glucose values between responders and non-responders (102.5 vs. 106.0,

conclusionsOverall, we observed that glucose control was not strongly associated with efficacy or toxicity in patients treated with ICIs.

Indexed as

CTLA-4immune checkpoint inhibitorsimmunotherapymetastatic melanomapatient outcomePD-1treatment toxicity

Identifiers

PMID41097756
PMCPMC12523285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.